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Our previous study has shown that AT406, a ﬁrst-in-class small molecular antagonist of IAPs (inhibitor of
apoptosis proteins), inhibits pancreatic cancer cell proliferation in vitro and in vivo. The aim of this
research is to increase AT406's sensitivity by adding short-chain C6 ceramide. We show that co-
treatment of C6 ceramide dramatically potentiated AT406-induced caspase/apoptosis activation and
cytotoxicity in established (Panc-1 and Mia-PaCa-2 lines) and primary human pancreatic cancer cells.
Reversely, caspase inhibitors largely attenuated C6 ceramide plus AT406-induced above cancer cell
death. Molecularly, C6 ceramide downregulated Bcl-2 to increase AT406's sensitivity in pancreatic cancer
cells. Intriguingly, C6 ceramide-mediated AT406 sensitization was nulliﬁed with Bcl-2 shRNA knockdown
or pretreatment of the Bcl-2 inhibitor ABT-737. In vivo, liposomal C6 ceramide plus AT406 co-
administration dramatically inhibited Panc-1 xenograft tumor growth in severe combined immunode-
ﬁcient (SCID) mice. The combined anti-tumor activity was signiﬁcantly more potent than either single
treatment. Expressions of IAPs (cIAP1/XIAP) and Bcl-2 were downregulated in Panc-1 xenografts with the
co-administration. Together, we demonstrate that C6 ceramide sensitizes AT406-mediated anti-
pancreatic cancer cell activity possibly via downregulating Bcl-2.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The prognosis of pancreatic cancer has been poor, and the long-
term survival of the patients is still dismissal [1e3]. Gemcitabine
and it-based combination treatments are currently being utilized
for chemotherapy of the pancreatic cancer patients [4]. Yet, the
response has not been satisfactory [1e3]. The research ﬁeld is
focusing on developing alternative anti-pancreatic cancer agents
[3,5,6]. It has also been our focus for many years [7].
The inhibitor of apoptosis proteins (IAPs), including X-linked IAP
(XIAP) and cellular IAP1/2 (cIAP1/cIAP2), are a family of key
apoptosis-inhibitory proteins [8]. Of which, XIAP directly inhibits
several key pro-apoptotic caspases, including caspase-3 and -7, and
-9 [8,9]. cIAP1 and cIAP2 are able of inactivating tumor necrosisgery, CPLA Bethune Interna-
Shijiazhuang, Hebei, 050082,
Zhao).
Inc. This is an open access article ufactor associated factor 2 (TRAF2) and TNF receptor-1/-2, thus
inhibiting caspase-8 [8e10]. Previous studies have shown that IAPs
play a pivotal role in apoptosis resistance in multiple cancer cells
[8e10]. IAPs are often over-expressed in pancreatic cancers, which
are critical for apoptosis inhibition and chemo-resistance [11]. IAPs
inhibition, on the other hand, would provoke pancreatic cancer cell
apoptosis [7,11].
Recent research efforts have developed a novel, potent and
orally bio-available antagonist of IAPs, named AT406 [12]. This ﬁrst-
in-class small molecular IAP antagonist directly binds to and in-
hibits IAP family members, such as XIAP, cIAP1 and cIAP2 [12]. Our
recent study has shown that AT406 induced cell death and
apoptosis in established and primary human pancreatic cancer cells
[7]. In vivo, oral administration of AT406 was found to efﬁciently
inhibit Panc-1 pancreatic tumor growth in severe combined
immunodeﬁcient (SCID) mice [7]. The aim of this current research
is to sensitize AT406's anti-cancer activity via supplementing short-
chain C6 ceramide.
Ceramides, enriched in cell membranes, are a family of lipidnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. C6 ceramide dramatically potentiates AT406-induced anti-pancreatic cancer
cell activity in vitro. Panc-1 cells (AeC), Mia-PaCa-2 cells (D), the primary human
pancreatic cancer cells (“Primary Pan Can”, E) or pancreatic epithelial HPDE6c7 cells
(F) were treated with applied concentrations of AT406 (“AT”, 10e1000 nM) or plus C6
ceramide (“C6”) for designated periods of time, cell survival was tested by CellTiter-Glo
luminescent assay (A and D-F) or the clonogenic assay (B); Cell proliferation was tested
by BrdU incorporation assay (C). “Ctrl” stands for untreated control cells (Same for all
ﬁgures). “Toge” stands for AT406 plus C6 ceramide treatment (Same for all Figures). All
values were expressed as mean ± SD (Same for all ﬁgures). For each assay, n ¼ 5.
Experiments in this ﬁgure were repeated three times, and similar results were ob-
tained. *p < 0.05 vs. group of “Ctrl”. #p < 0.05 vs. AT406 only treatment.
X. Zhao et al. / Biochemical and Biophysical Research Communications 479 (2016) 166e172 167signaling molecules which are important in regulating key cellular
functions, including cell growth, differentiation, apoptosis, and
autophagy [13,14]. The short-chain cell permeable ceramides (C2,
C4, C6 and C8) have demonstrated promising anti-cancer activity,
alone or in combination with conventional anti-cancer agents [14].
Existing evidences have shown that short-chain C6 ceramide could
dramatically augment the anti-tumor activity by doxorubicin,
paclitaxel (Taxol), histone deacetylase inhibitor (HDACi) and
vincristine [15e17]. In this report, we demonstrate that C6 cer-
amide could also sensitize AT406's activity against human
pancreatic cancer cells.
2. Materials and methods
2.1. Reagents, chemicals and antibodies
AT406was purchased from Selleck (Shanghai, China). Liposomal
C6 ceramide and free C6 ceramide were provided by Dr. Xiwen
Fan's Lab [18] The caspase-3 speciﬁc inhibitor Ac-DEVD-CHO, the
caspase-9 inhibitor Ac-LEHD-CHO and the pan caspase inhibitor
Ac-VAD-CHO were from Calbiochem (La Jolla, CA). All the anti-
bodies utilized in the study were obtained from Cell Signaling Tech
(Shanghai, China). Cell culture reagents were obtained from Gibco
(Shanghai, China).
2.2. Cell culture
Cultures of established human pancreatic cancer cell lines
(Panc-1 and Mia-PaCa-2) and the pancreatic epithelial cell line
HPDE6c7 were described previously [7].
2.3. Primary culture of human pancreatic cancer cells
As described [7], the fresh pancreatic cancer specimens from
informed-consent patients were washed and minced. Resolving
cancer tissues were then digested [7]. Afterwards, the single-cell
suspensions were pelleted and washed. Primary cancer cells were
then cultured in the medium described [19]. The protocol was
approved by the Institutional Review Board and the Ethics Com-
mittee of authors' institutions. All studies were conducted in
accordance with the principles expressed in the Declaration of
Helsinki.
2.4. Cell viability assay
The CellTiter-Glo luminescent cell viability assay kit was applied
to evaluate cell viability according to the manufacturer's in-
structions (Promega, Shanghai, China). The detailed protocol was
described in our previous study [7]. Luminescence OD, indicator of
cell viability, was recorded by a Fluorescence/Multi-Detection
Microplate Reader (Synergy 2, BioTek, Winooski, VT) [7].
2.5. Clonogenic assay
As described [7], cells were seeded at 3000/well onto 6-well
plates. Following the applied treatments, cells were then allowed
to grow for additional 10 days. The colonies were then ﬁxed and
manually counted.
2.6. Cell proliferation assay
The BrdU assay kit (Cell Signaling Technology, Shanghai, China)
was applied to test cell proliferation following applied treatment
[7].2.7. Caspase activity assay
Following treatment of cells, cytosolic proteins (25 mg per
treatment) [7] were incubated with the caspase assay buffer [7]
with corresponding caspase-3/-9 substrate [7]. The released AFC
was measured via a multi-detection microplate reader with exci-
tation of 400 nm [7].2.8. TUNEL staining assay
Cell apoptosis was detected by terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) In Situ Cell Death
Detection Kit (Roche, Shanghai, China) as described [7]. TUNEL ratio
(TUNEL/DAPI  100%) was recorded under a ﬂuorescence micro-
scope (Zeiss, 1: 100 magniﬁcation). For each condition, a total of ten
X. Zhao et al. / Biochemical and Biophysical Research Communications 479 (2016) 166e172168random views containing at least 500 cells were included to count
TUNEL ratio.2.9. Annexin V assay of apoptosis
The FITC-conjugated Annexin V (Bender, Burlingame, CA)
staining assay was performed to quantify cell apoptosis after
treatment [7].2.10. Western blot assay
The detailed protocol for Western blot assay was described
previously [19]. In brief, equal amounts of cytosol protein extracts
per sample were resolved by SDS-PAGE and analyzed by Western
blot. The antibody-antigen binding was visualized via the Super-
Signal West Pico ECL substrates (Pierce). Band intensity (total
gray) was quantiﬁed via the Image J software.A. B. C.
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Fig. 2. C6 ceramide potentiates AT406-induced pancreatic cancer cell apoptosis. Panc-1 c
the pancreatic epithelial HPDE6c7 cells (I) were treated with applied concentration of AT40
activation and cell apoptosis were tested by listed assays (A-E, G-I); For E and F, Panc-1 ce
(“DEVD”, 40 mM), the caspase-9 inhibitor Ac-LEHD-CHO (“LEHD”, 40 mM) or the pan casp
assay, n ¼ 5. Experiments in this ﬁgure were repeated three times, and similar results were o
#p < 0.05 vs. group of “DMSO (0.1%)” (E and F).2.11. Bcl-2 shRNA knockdown
Brieﬂy, cells were seeded onto the polybrene (Sigma)-coated 6-
well plate with 50% conﬂuence, and were infected with the lenti-
viral Bcl-2 shRNA (“-1/-2”) [7] for 24 h. Cells were then subjected to
puromycin selection. Bcl-2 downregulation in stable cells was
conﬁrmed by Western blot assay [7]. Control cells were infected
with same amount of scramble nonsense control shRNA lentivirus
(Santa Cruz).
2.12. Mouse xenograft model and immunohistochemistry (IHC)
staining
Animal studies were approved by the IACUC and Ethics Com-
mittee of all authors' institutions. Panc-1 cells (1  107 per mouse)
were injected s.c. into the right ﬂanks of male severe combined
immunodeﬁcient (SCID) mice (Animal Research Centre, Shanghai,
China). When established tumors were around 0.1 cm3 in volume,D.
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Fig. 3. C6 ceramide downregulates Bcl-2 to increase AT406's sensitivity in
pancreatic cancer cells. Panc-1 cells (A) or the primary human pancreatic cancer cells
(“Primary Pan Can”, B) were treated with AT406 (“AT”, 500 nM) or plus C6 ceramide
(“C6”, 10 mM) for 24 h, expression of listed proteins was tested by Western blot assay.
Panc-1 cells (C) or the primary human pancreatic cancer cells (D), pretreated with/out
ABT-737 (“ABT”, 10 mM, 1 h), were stimulated with AT406 (“AT”, 500 nM) or plus C6
ceramide (“C6”, 10 mM) for 72 h, cell viability was tested by the CellTiter-Glo assay.
Stable Panc-1 cells with scramble control shRNA (“C-shRNA”) or Bcl-2 shRNA (“-1/-2”)
were treated with AT406 (500 nM) or plus C6 ceramide (“C6”, 10 mM) for 72 h, Bcl-2
expression (E) and cell viability (F) were tested. Relative expression of listed pro-
teins (vs. Tubulin) was quantiﬁed (A, B and E, lower panels). Experiments in this ﬁgure
were repeated three times, and similar results were obtained. *p < 0.05 vs. group of
“Ctrl”.#p < 0.05 vs. AT406 only treatment.
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vehicle (Saline, oral gavage), AT406 (5 mg/kg, oral gavage, at Day-1,
2, 3, 8,15 and 22) [7] and/or liposomal C6 ceramide (25mg/kg, i.v. at
Day-1, 2, 3, 8, 15 and 22) [20]. Tumor volume was calculated using
the described formula [7]. For IHC study, Panc-1 xenografts were
ﬁxed; Tissue parafﬁn sections (4-mm) were blocked and incubated
with primary antibody (Bcl-2, 1:50). The HRP-conjugated second-
ary antibody (1: 50) was then added, followed by 3,30-dia-
minobenzidine color development.
2.13. Statistical analysis
Statistical analysis was carried out via the SPSS 18.0 software
(Chicago, IL). Results were compared via one-way analysis of vari-
ance (ANOVA) followed by Turkey's test. All values were expressed
as mean ± standard deviation (SD). A p value of less than 0.05 was
considered statistically signiﬁcant [7].
3. Results
3.1. C6 ceramide dramatically potentiates AT406-induced anti-
pancreatic cancer cell activity in vitro
This study focused on the potential effect of short-chain C6
ceramide on AT406's activity in pancreatic cancer cells. Cultured
Panc-1 pancreatic cells were treated with AT406 or plus C6 cer-
amide. In line with our previous ﬁndings [7], we showed that
AT406 dose-dependently inhibited Panc-1 cell survival (Fig. 1A).
Yet, AT406's activity alone was moderate, with the IC-50 over
500 nM (Fig. 1A). Signiﬁcantly, co-treatment with C6 ceramide (at
10 or 25 mM) remarkably potentiated AT406's sensitivity, leading to
a dramatic viability reduction in Panc-1 cells (Fig. 1A). The IC-50 of
AT406 decreased to less than 50 nM when combined with C6 cer-
amide (10 or 25 mM) (Fig. 1A). Notably, treatment with C6 ceramide
alone (at 10 or 25 mM) only induced minor viability reduction in
Panc-1 cells (Fig. 1A). Yet, a low concentration of C6 ceramide
(1 mM) showed no such effects (Fig. 1A).
The clonogenicity assay results in Fig. 1B demonstrated that
AT406 dose-dependently decreased the number of viable Panc-1
colonies, which was again facilitated with co-treatment of C6 cer-
amide (10 mM) (Fig. 1B). To test Panc-1 cell proliferation, BrdU
incorporation assay [7] was applied. Results showed that the anti-
proliferative activity by AT406 was largely enhanced when com-
bined with C6 ceramide (10 mM) (Fig. 1C). Treatment C6 ceramide
(10 mM) alone only slightly inhibited Panc-1 cell colony formation
(Fig. 1B) and proliferation (Fig. 1C).
We also tested the effect of C6 ceramide on AT406 in other
pancreatic cancer cells. CellTiter-Glo assay results showed that C6
ceramide (10 mM) largely potentiated AT406 (500 nM)-induced
death of Mia-PaCa-2 cells (Fig. 1D) and primary human pancreatic
cancer cells (Fig. 1E). On the other hand, the same AT406 plus C6
ceramide regimen was non-cytotoxic to HPDE6c7 cells, which are
normal pancreatic epithelial cells (Fig. 1F). Collectively, these re-
sults demonstrate that co-treatment of C6 ceramide dramatically
sensitizes AT406-induced anti-pancreatic cancer cell activity in
vitro.
3.2. C6 ceramide potentiates AT406-induced pancreatic cancer cell
apoptosis
Our previous study has shown that AT406 provoked apoptotic
cell death in pancreatic cancer cells [7], we thus studied the po-
tential effect of C6 ceramide on the process. Treatment with AT406
(500 nM) again induced activation of caspase-3 (Fig. 2A) and
caspase-9 (Fig. 2B) in Panc-1 cells. Further, the TUNEL percentage(Fig. 2C) and the Annexin V intensity OD (Fig. 2D) were both
increased following AT406 (500 nM) treatment. Remarkably, such
pro-apoptotic activity by AT406 was signiﬁcantly augmented with
co-treatment of C6 ceramide (Fig. 2AeD). The latter alone only
induced minor cell apoptosis (Fig. 2AeD). Importantly, as shown in
Fig. 2E and F, the caspase-3 speciﬁc inhibitor Ac-DEVD-CHO, the
caspase-9 inhibitor Ac-LEHD-CHO or the pan caspase inhibitor Ac-
VAD-CHO all largely attenuated AT406 plus C6 ceramide-induced
Panc-1 cell apoptosis (Fig. 2E) and death (Fig. 2F). These results
X. Zhao et al. / Biochemical and Biophysical Research Communications 479 (2016) 166e172170suggested that C6 ceramide potentiated AT406-induced apoptotic
death of pancreatic cancer cells. Similarly in primary human
pancreatic cancer cells (Fig. 2G and H), C6 ceramide signiﬁcantly
facilitated AT406-induced cell apoptosis. Notably, the same co-
treatment failed to induce signiﬁcant apoptosis in the non-
cancerous HPDE6c7 epithelial cells (Fig. 2I). Collectively, these re-
sults suggest that C6 ceramide potentiates AT406-induced
pancreatic cancer cell apoptosis.
3.3. C6 ceramide downregulates Bcl-2 to increase AT406's
sensitivity in pancreatic cancer cells
Our recent study has implied the Bcl-2, a well-known anti-
apoptosis protein [21], could be a major resistance factor of AT406
in pancreatic cancer cells [7]. We found that Bcl-2 inhibition or
shRNA knockdown potentiated AT406-induced pancreatic cancer
cell death [7]. We therefore examined the potential effect of C6
ceramide (or plus AT406) on Bcl-2 expression in pancreatic cancer
cells. In line with our previous ﬁndings [7], Fig. 3A results showed
that AT406 treatment in Panc-1 cells downregulated key IAPs18
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The above results suggest that C6 ceramide-mediated AT406
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3.4. Liposomal C6 ceramide sensitizes AT406-induced anti-
pancreatic cancer activity in vivo
At last, by using the Panc-1 xenograft SCID mice model [7], we
tested the potential effect of C6 ceramide on AT406-induced anti-
tumor activity in vivo. Since free C6 ceramide is not soluble when
given in vivo, we hereby applied the liposomal C6 ceramide (a gift
fromDr. Fan [18]). As shown in Fig. 4A, oral administration of AT406
(5 mg/kg, gavage) inhibited Panc-1 xenograft growth in SCID mice.
Signiﬁcantly, co-administration of the liposomal C6 ceramide
(“Lipo C6”, i.v., at 25 mg/kg) dramatically potentiated AT406's anti-
tumor activity, leading to profound inhibition on Panc-1 xenograft
growth (Fig. 4A). The anti-tumor activity by the combination was
apparently superior than either single treatment (Fig. 4A). Treat-
ment with liposomal C6 ceramide alone also exerted moderate
inhibition on Panc-1 xenograft growth (Fig. 4A). Daily tumor
growth (mm3 per day)was again lowest in AT406 plus liposomal C6
co-administration mice (Fig. 4B). AT406 or liposomal C6 alone less
efﬁciently inhibited tumor growth (Fig. 4B).
Notably, the mice body weights were not affected by the AT406
and/or liposomal C6 treatment (Fig. 4C). We also failed to observe
any signs of toxicities in the tested animals. Therefore, the SCID
mice appeared well-tolerated to the single or the combination
treatment. When analyzing the apoptosis molecule in Panc-1 tu-
mor masses, we showed expressions of cIAP1, XIAP and Bcl-2 were
all downregulated in AT406 plus liposomal C6-treated Panc-1 xe-
nografts (Day-3 after administration, Fig. 4D). Notably, our previous
studies found that Bcl-2 was not affected by AT406 single treatment
[7]. Expression of cleaved-caspase-3, the indicator of cell apoptosis,
was signiﬁcantly increased in the combination-treated tumors
(Fig. 4D). IHC staining assay further conﬁrmed Bcl-2 down-
regulation in Panc-1 tumors with the co-administration (Fig. 4E).
Therefore, the signaling results in Panc-1 tumor masses are
consistent with the in vitro ﬁndings.
4. Discussions
The results of our recent study [7] have indicated that Bcl-2 may
act as the primary resistance factor of AT406 [7]. We previously
showed that AT406 failed to affect expression of Bcl-2 in human
pancreatic cancer cells [7]. Yet, shRNA knockdown or pharmaco-
logical inhibition (ABT-737) of Bcl-2 dramatically potentiated
AT406-induced lethality in humanpancreatic cancer cells [7]. In the
present study, we demonstrated that C6 ceramide downregulated
Bcl-2 in pancreatic cancer cells, which could be the reason for the
subsequent AT406 sensitization. Notably, ABT-737 or Bcl-2 knock-
down almost nulliﬁed C6 ceramide-mediated AT406 sensitization
in pancreatic cancer cells. Our results of Bcl-2 downregulation by
C6 ceramide were consistent with other studies. For example, Ji
et al., have shown C6 ceramide, alone or together with Doxorubicin,
signiﬁcantly downregulated Bcl-2 in multiple cancer cell lines [17].
It will be worthy testing the underlying mechanisms of Bcl-2
downregulation by C6 ceramide.
Although exerting promising anti-cancer cell activity [23], C6
ceramide and other short-chain ceramides have extremely poor
solubility, which signiﬁcantly limited their applications in vivo
[16,24e26]. Therefore, liposome-based nanotechnologies have
been applied for package and the system delivery of these short-
chain ceramides [16,24e26]. Existing evidences have suggested
that liposome package of C6 ceramide could offer its rapid tissue
distributionwhen given systematically (i.v.) [24]. Further, liposomal
C6 ceramide showed no apparent adverse effects [18,20,24].
Signiﬁcantly, liposomal C6 ceramide demonstrated selectivetoxicity only to cancerous cells, yet sparing normal non-cancerous
cells [16,18,20,25,26]. Here, we showed that co-administration of
liposomal C6 ceramide in SCID mice largely augmented AT406-
induced anti-cancer activity in vivo. These results suggest that
liposomal C6 ceramide could act as an important adjuvant for
AT406 to kill pancreatic cancer cells.
Pancreatic cancer is still one of the most aggressive human
malignancy with an extremely poor prognosis [27]. Many of the
pancreatic cancer cells are strikingly resistant to current conven-
tional gemcitabine-based treatments, which have failed to signiﬁ-
cantly improve patients' survival [27]. It is therefore extremely
important to develop novel therapeutic agents against this devas-
tating disease [27]. The results of the current report indicate that
AT406 plus C6 ceramide may be worthy further testing in other
pancreatic cancer models.
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